![]() |
The Difference in Guanfacine Formulations for ADHD...
December 1, 2014 - Clinical , Featured By: Katharine Cimmino, Editor-in-Chief – Attention-deficit/hyperactivity disorder (ADHD) is the most common pediatric psychiatric disorder, and it affects the education, social interactions, and over-all wellbeing of both children and adolescents.1 Symptoms of ADHD can persist into adulthood, and those with this disorder are more likely to suffer from other mental health co-morbidities.2 According to guidelines… |
![]() |
Using Bacteriophage Enzymes to Stay One Step Ahead of M...
December 1, 2014 - Featured , In the News / Politics By: Davidta Brown, Copy Editor [Content-Focused] – It’s difficult to have a discussion about antibiotics without mentioning the developing crisis of antibiotic-resistance. Pathogens like MRSA (methicillin-resistant Staphylococcus aureus) have become a part of the general public’s consciousness – a household name and a community-acquired “superbug.” With the last new class of antibiotics developed in the… |
![]() |
Recombinant Factor IX (Alprolix) Brings Hope for Hemoph...
December 1, 2014 - Featured , In the News / Politics By: Benedette Cuffari, BS Toxicology Candidate c/o 2015 – Hemophilia B is an inherited bleeding disorder that is caused by a substantially reduced or complete lack of blood clotting factor IX. Therefore, people suffering from hemophilia B experience bleeding episodes that cause pain, irreversible joint damage, and life threatening hemorrhages. Approximately 28,000 people are currently… |
![]() |
Off-Label Antidepressant Use in Pediatric Patients with...
November 1, 2014 - Clinical , Featured By: Jacqueline Meaney, PharmD Candidate c/o 2015, University at Buffalo: School of Pharmacy and Pharmaceutical Sciences — Psychotropic medications are typically used in conjunction with cognitive behavioral therapy to treat behavioral problems that affect children with autism spectrum disorder (ASD). Symptoms of ASD typically include a need for routines (change intolerance), difficulty with verbal and… |
![]() |
Pradaxa® vs Warfarin...
November 1, 2014 - Featured , In the News / Politics By: Kevin Lin, PharmD Candidate c/o 2015 — The FDA recently completed an observational cohort study that compared Pradaxa® (dabigatran) to warfarin for rates of ischemic stroke, intracranial hemorrhage, major gastrointestinal bleed, myocardial infarction, and death. The study enrolled more than 134,000 patients, with 64% over the age of 65 and found a lower risk… |
![]() |
Accountable Care Organizations...
November 1, 2014 - Featured , In the News / Politics By: Stephanie Chiu and Elissa Tam, PharmD Candidates c/o 2015 — According to the Dartmouth Atlas project, health care spending in the United States has risen dramatically and yet health outcomes are not improving; meanwhile, many other countries that spend far less per person than the United States have better health outcomes.1 Studies have since… |
![]() |
Anticoagulation in Pregnant Women: Which Medications ar...
October 1, 2014 - Clinical , Featured By: Diana Gritsenko, PharmD Candidate 2015 – Multiple complications can arise during pregnancy. While venous thromboembolism (VTE) has a prevalence rate of just 0.06% it is one of the leading causes of maternal mortality. It is recommended that at-risk pregnant women receive anticoagulation therapy for a minimum of 3 months and VTE prophylaxis for the… |
![]() |
FDA-Approved Afrezza: An Inhaled Alternative to Injecta...
October 1, 2014 - Featured , In the News / Politics By: Elissa Tam, PharmD Candidate c/o 2015 – Patients with Type 1 or Type 2 diabetes who cannot control their glucose levels simply by taking oral medications have to inject insulin daily. They also have to measure their glucose levels by using strips and lancets on a regular basis. For patients, especially elderly ones, the… |
![]() |
HIV Pre-Exposure Prophylaxis...
September 1, 2014 - Clinical , Featured By: Elissa Tam PharmD Candidate c/o 2015 – HIV/AIDS continues to be a persistent problem in the United States and in various countries around the world. In 2010 alone, there were around 47,500 new HIV infections in the United States with about 1.1 million Americans living with HIV at the end of 2010.1 When left… |
![]() |
Reservoir of Migraine Therapies Includes Analgesics, AE...
September 1, 2014 - Clinical , Featured By Davidta Brown, Senior Staff Editor – The pain, nausea, and light or sound sensitivity that comprise a migraine attack afflict more than 10% of individuals around the world, easily making migraines one of the most globally debilitating diseases of the present day.1 According to the International Headache Society (IHS), migraines are defined by both… |
![]() |
Pediatric Hypertension...
August 1, 2014 - Clinical , Featured By: Anthony Botte and Tyler Valente, PharmD Candidates c/o 2016 – Diseases which are prevalent within the pediatric population require distinct protocols for treatment accompanied by the utmost care and precision. Pediatric hypertension (HTN) is one disease state in particular that has come to the forefront of medical practice in the United States over the… |
![]() |
Quantifying the Benefits of Pharmacist Prescribing Powe...
July 1, 2014 - Featured , Professional Advice / Opinions By Davidta Brown, Senior Staff Editor – The idea of granting pharmacists the right to prescribe, as well as to counsel and dispense, has long been a source of controversy among healthcare professionals. A study out of the University of Alberta in Canada, published online in mid-April, provided some much needed concrete data for an… |
![]() |
Recent Advances in HIV Treatment...
July 1, 2014 - Clinical , Featured By: Jenny Park PharmD Candidate c/o 2015 – A series of broad HIV specific monoclonal antibodies (mAb) have been isolated and been shown to bind to CD4 binding sites, V1/V2 loops, V3/V4 loops, glycans, and proximal external regions. It has been shown that administration of a “cocktail” of HIV-1 specific monoclonal antibodies along with single… |
![]() |
The Dangers of Intrathecal Baclofen...
June 1, 2014 - Clinical , Featured By: Ada Seldin, Staff Editor – Intrathecal baclofen (ITB) is indicated for the treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, spinal ischemia or tumor, transverse myelitis, cervical spondylosis, cerebral palsy, and degenerative myelopathy.1 Baclofen inhibits both monosynaptic and polysynaptic reflexes at the spinal cord level by decreasing excitatory neurotransmitter release from… |
![]() |
New Considerations for Testosterone Therapy...
June 1, 2014 - Featured , In the News / Politics By: Jenny Park PharmD Candidate c/o 2015 – Testosterone is a hormone essential to male development. However, treatment of testosterone deficiency is FDA approved only when accompanied with another medical condition such as failure of testicles to produce testosterone due to chemotherapy or even genetic conditions.1 In 2011, 5.3 million prescriptions for testosterone were written… |
![]() |
Pharmacy Lobby Day...
June 1, 2014 - In the News / Politics By: Melissa Roy, Co-Copy Editor [Graphics Focused] – During Pharmacy Lobby Day, pharmacists and students from all over New York gather at the capitol in Albany to meet with various members of Congress to discuss the state of pharmacy. This year, similar to previous years, a group of students and faculty from St. John’s University… |
![]() |
Scientists Finally Discover How HIV Progresses to AIDS...
June 1, 2014 - Featured , In the News / Politics By: Sabrina Ahmed, PharmD Candidate c/o 2017 – Over the decades, one of the biggest mysteries encountered by researchers has been why so many CD4 T-cells die when one is infected with Human Immunodeficiency Virus (HIV).1 CD4 T-cells are an integral part of the immune system as they locate pathogens and signal other immune cells… |
![]() |
FDA Approves Drug Elosulfase Alfa (Vimizim™) for Muco...
May 1, 2014 - Featured , In the News / Politics By: Erica Dimitropoulos Co-Copy Editor [Content- Focused] – On February 14, 2014, elosulfase alfa (Vimizim™) became an FDA-approved enzyme replacement therapy for Morquio A Syndrome, a type of mucopolysaccharidosis (MPS IVA).1 Elosulfase alfa was granted priority review and was also the first drug to receive the Rare Pediatric Disease Priority Review Voucher that motivates the development… |
![]() |
Possible New Prostate Cancer Screening...
May 1, 2014 - Featured , In the News / Politics By: Fatema Elias, Senior Staff Editor – Prostate cancer occurs when abnormal cells form in the tissues of the prostate gland. It often develops in men over the age of 50, and the numbers of estimated new cases and of deaths from prostate cancer in the United States in 2013 are 238,590 and 29,720, respectively.1… |
![]() |
The Use of Topical Opioid Treatment for Pressure Ulcer ...
May 1, 2014 - Clinical , Featured By: Katharine Cimmino, Editor-in-Chief – Pressure ulcers can be a painful condition decreasing the quality of life of patients and prolonging hospital stays.1 About 10% of hospital inpatients and 26% of hospice admissions have pressure sores.2 Pressure ulcers are injuries that occur when pressure is applied for prolonged periods of time over bony prominences.1 There… |
![]() |
Brown-Bag Event...
May 1, 2014 - Events , Featured By: Hayeon Na, Co-Copy Editor (Content Focused) – On February 26th, 2014, pharmacists, clinical faculty, and pharmacy students from St. John’s University College of Pharmacy and Health Sciences gathered at the Freeport Memorial Library for a “Brown Bag,” one of the yearly calendar events at the public library. This event was conducted through the joint… |
![]() |
New Strides in Lupus Treatment...
April 1, 2014 - Featured , In the News / Politics By: Daniel Mathan, PharmD Candidate c/o 2016, Anita Kachappilly, PharmD Candidate c/o 2016, & Amrita Singh, PharmD Candidate c/o 2015 – Systemic lupus erythematosus (SLE) is a debilitating autoimmune disease that affects multiple organs in the body and can potentially become life threatening.1 The incidence of SLE is about 50 cases for every 100,000 people; it… |
![]() |
Riociguat (Adempas®) New Drug for Pulmonary Hypertens...
April 1, 2014 - Clinical , Featured By: Hayeon Na, Co-Copy Editor [Content-Focused] – On October 8th of 2013, Bayer’s new drug riociguat (Adempas®) was approved for the treatment of patients whose pulmonary hypertension (PH) belongs in WHO groups 1 and 4.1 Riociguat (Adempas®) is a soluble guanylate cyclase (sGC) stimulator, and currently the only one of its kind on the market.… |
![]() |
Methadone Associated Arrhythmias on the Rise...
March 1, 2014 - In the News / Politics By: Jenny Park, PharmD Candidate c/o 2015 – Methadone maintenance therapy is prescribed for opioid dependency. Many HIV patients who were former injection drug abusers rely on methadone maintenance. Although there is limited data, research suggests lamivudine, ritonavir, and zidovudine to be the most common concomitant drugs in methadone associated torsades and prolonged QT interval.1… |
![]() |
A Brave New World for Lipid Management...
March 1, 2014 - Featured , In the News / Politics By: Amrita Singh, PharmD Candidate c/o 2015 – Last November, the American College of Cardiology and the American Heart Association released new lipid guidelines, which will transform the way we manage our patients with hyperlipidemia. Earlier, lipid management was based on the ATP-III guidelines, which emphasized the use of several lipid-lowering medications to reach target… |
![]() |
Psychiatric Prescriptions in the Fight Against Juvenile...
March 1, 2014 - Clinical , Featured By: Davidta Brown, Senior Staff Editor – In August 2013, the results of a yearlong safety study were published in the Journal of American Medical Association (JAMA) Psychiatry.1 The study, which followed the health status of about 43,000 youths aged 6 to 24, confirmed and built upon a previously noted trend in adults: that the… |
![]() |
To Defend the People...
February 1, 2014 - Featured , Professional Advice / Opinions By: Davidta Brown, Senior Staff Editor – As the world’s largest market for pharmaceuticals, the United States receives many medications manufactured abroad.1 Patients, physicians, and pharmacists defer the responsibility of ensuring the quality of these imported drugs to the FDA, but it only takes one report of deceit in the pharmaceutical industry for this trust… |
![]() |
Long Term PPI Use Heightens Concern of Associated Healt...
February 1, 2014 - Clinical , Featured By: Tamara Yunusova, Senior Staff Editor – Proton Pump Inhibitors (PPIs) are acid-reducing agents that have multiple uses in the treatment and prophylaxis of conditions such as peptic ulcer diseases, H. Pylori infection, Zollinger-Ellison syndrome, GERD, and NSAID gastroduodenal ulcers. Their versatility in treating a wide range of conditions, unparalleled efficacy over their Histamine-2-receptor antagonist… |
![]() |
Low Literacy and Medication Management?...
February 1, 2014 - Professional Advice / Opinions By: Jenny Park, Pharm. D. Candidate c/o 2015 – As the Affordable Care Act brings health care to many people who are currently uninsured, healthcare providers should expect an increase in the number of patients who don’t understand their plan, disease states, and medications. Health literacy is defined as “the degree to which individuals have… |
![]() |
The Increasing Roles of Pharmacists in Transplant Outco...
February 1, 2014 - Featured , In the News / Politics By: Jenny Park, PharmD Candidate c/o 2015 – Medication adherence is a big part of a patient’s success in managing their health conditions. The Annals of Internal Medicine estimated that the cost of medication non-adherence may reach up to $289 billion each year.1 It is crucial for organ transplant patients to take powerful immunosuppressants to… |
![]() |
Dengue Fever: Where Do We Go From Here?...
February 1, 2014 - In the News / Politics By: Sherin Pathickal, PharmD Candidate c/o 2016 – Dengue Fever, widely known as “break-bone fever,” is an illness that causes pain in the joints and muscles, and is often described by those infected as comparable to the feeling of breaking a bone.1 It is spread by mosquitoes and has a painful array of symptomology such… |
![]() |
Pharmacy Across the Border: An Interview with Sherif Gu...
February 1, 2014 - Featured , Professional Advice / Opinions By: Sang Hyo Kim, Staff Editor – For the brand new year, we present an interview with Sherif Guorgui, the current Vice-President of Pharmacy at the Ontario Pharmacists Association and the former 2011-2012 President of the Ontario College of Pharmacists in Canada. Mr. Guorgui graduated in 1998 from the Faculty of Pharmacy at the University… |
![]() |
Dr. Robert Mangione – From Student to Provost of ...
January 1, 2014 - Featured , Professional Advice / Opinions By: Katharine Cimmino, Editor-in-Chief and Melissa Roy, Co-Copy Editor [Graphics-Focused] – Dr. Mangione has been a prominent member here at St. John’s University both as a student and as a leader. Before becoming our dedicated Provost, Dr. Mangione was the Dean of the College of Pharmacy and Health Sciences since 1999. He joined the St.… |
![]() |
New Alternative First Line Therapy for EGFR NSCLC...
January 1, 2014 - In the News / Politics By: Jenny Park, PharmD Candidate c/o 2015 – On July 12, 2013, the FDA approved afatinib (GilotrifTM) as a new first-line treatment for patients with late-stage non-small cell lung cancer (NSCLC), a type of carcinoma where specific types of epidermal growth factor receptor (EGFR) gene mutations are expressed.1 The drug afatinib irreversibly blocks EGFR, also… |
![]() |
New Hepatitis C Drug Receives FDA Approval...
January 1, 2014 - Clinical , Featured By: Ada Seldin, Staff Editor – On November 22, 2013, simeprevir (Olysio®), a new agent to treat chronic hepatitis C, received approval under the FDA’s priority review program. Simeprevir is an NS3/4A protease inhibitor that blocks the replication of the hepatitis C virus. Two other drugs from the same class, boceprevir and telaprevir, which were… |
![]() |
The Use of Methadone in Neuropathic Pain...
January 1, 2014 - Clinical By: Neal Shah, PharmD, MD/PhD Student c/o 2021, West Virginia University School of Medicine – Methadone is a powerful long-acting mu-opioid agonist that has been traditionally used in the management of chronic pain, treatment of pain refractory to certain opioid agents, and maintenance of opioid addiction.1-5 While neuropathic pain is not traditionally linked to mu-opioid… |
![]() |
Say Hello to JNC8: New Hypertension Guidelines...
January 1, 2014 - Featured , In the News / Politics By: Frances Trosa PharmD Candidate c/o 2015 – After much anticipation, the report from the Eighth Joint National Committee (JNC 8) has arrived! Panel members appointed to the committee have created evidence – based recommendations to assist physicians in managing hypertensive patients. A major difference between the JNC 7 report and the JNC 8 report… |
![]() |
The Blunt Truth...
January 1, 2014 - Featured , In the News / Politics By: Katharine Cimmino, Editor-in-Chief – Marijuana, also known as “grass,” “pot,” “joint,” “weed,” “reefer,” “hashish,” and “Mary Jane,” is a very popular illicit drug.1 According to the National Survey on Drug Use and Health, “In 2012, 5.4 million persons aged 12 or older used marijuana on a daily or almost daily basis in the past 12… |
![]() |
Direct Association of HIV and Early Kidney Damage in Wo...
January 1, 2014 - Featured , In the News / Politics By: Elizabeth Kopec, PharmD Candidate c/o 2014, South University School of Pharmacy at Columbia, SC – Human immunodeficiency virus (HIV) is a global pandemic, with approximately 35.3 million people infected in 2012. The United States currently has 1.3 million people living with HIV, with 20,000 deaths occurring every year due to acquired immune deficiency syndrome… |
![]() |
Newly Approved: Macitentan (Opsumit®)...
December 1, 2013 - Clinical , Featured By: Rebecca Gilene, PharmD Candidate c/o 2014, St. Louis College of Pharmacy – The FDA approved macitentan (Opsumit®) on October 18, 2013 for the treatment of pulmonary arterial hypertension.1 Pulmonary arterial hypertension, often referred to as PAH, is a disease characterized by high blood pressure in the arteries between the heart and lungs. An increase… |
![]() |
Possible Inhaled Option for Diabetics...
December 1, 2013 - In the News / Politics By: Sang Hyo Kim, Staff Editor – Near the end of December, the pharmaceutical company, MannKind Corp, will submit their clinical data to the U.S Food and Drug Administration for the approval of an inhaled dosage form of insulin, Afrezza®.1 Administered with the Dreamboat inhaler, this inhaled dosage form delivers insulin packaged into single dose… |
![]() |
Ponatinib Taken Off the Market...
December 1, 2013 - In the News / Politics By: Sherine Jaison, PharmD Candidate c/o 2015 – The leukemia chemotherapy drug ponatinib (Iclusig) has just been taken off the market. The drug was under investigation by the Food and Drug Administration (FDA) following several reports of serious and life threatening blood clots and narrowing of the blood vessels.1 Ponatinib is a BCR-ABL tyrosine kinase… |
![]() |
Provider Status for Pharmacists: Call to Action or Dist...
December 1, 2013 - Featured , In the News / Politics By: Samantha Schmidt, PharmD Candidate c/o 2014, Palm Beach Atlantic University – The role of pharmacists in healthcare has grown exponentially over the years. Pharmacists now provide advanced patient-centered care services including coordination of medications during transitions of care, comprehensive medication reviews with medication monitoring, chronic disease management, disease education, prevention and wellness services, and… |
![]() |
Zecuity(TM): Novel Treatment Option for Migraines...
November 1, 2013 - Clinical By: Arya Mathew, PharmD Candidate c/o 2014 – About twelve percent of the U.S. population suffers from migraines, affecting adult women three times more than adult men. Migraines are returning attacks of moderate to severe, throbbing or pulsing pain, usually on one side of the head. Along with the severe pain, migraine sufferers also experience… |
![]() |
Moving Towards Provider Status: An Interview with Sandr...
November 1, 2013 - Professional Advice / Opinions By: Hayeon Na, Co-Copy Editor and Sang Hyo Kim, Staff Editor – In Volume 1 Issue1 of the Rho Chi Post, we were honored to have an interview with Sandra Leal, PharmD, MPH, FAPhA, CDE, and Director of Clinical Pharmacy at El Rio Health Center in Tucson, Arizona. She had started a petition to support… |
![]() |
The Third Wheel or the Steering Wheel? Pharmacists on t...
November 1, 2013 - Professional Advice / Opinions By: Joshua Bliss, PharmD Candidate c/o 2016 – Doctor – a word often utilized by both professionals and the general public alike to describe a physician. “Doctor” finds its origins in the Latin word for “teacher.” The word “physician,” however, carries a more complicated origin. It is derived from Latin’s “physicum,” meaning remedy.1 In Luke… |
![]() |
“Cowcatcher” Enzyme Catching Medical Attention...
November 1, 2013 - Featured , In the News / Politics By: Ansel Oommen, BS Toxicology Candidate c/o 2014 – DNA damage is the driving force behind aging, and, on a more serious note, the development of cancers.1 While the stresses of life can be taxing on cells, the human body possesses a remarkable repair mechanism to remedy them. Researchers from the University of Texas Medical… |
![]() |
Ceftriaxone Induced Hemolytic Anemia...
November 1, 2013 - Clinical , Featured By: Samad Tirmizi, PharmD Candidate c/o 2014 – Hemolytic anemia (HA) is a type of anemia that occurs due to the breakdown of red blood cells. It is classified as intrinsic and extrinsic according to causative factors. Medication induced hemolytic anemia is an example of extrinsic, while genetic predisposition is an intrinsic factor. Drug induced… |
![]() |
Nature’s Remedy… in a More Palatable Dosage Form...
November 1, 2013 - Featured , In the News / Politics By: Davidta Brown, Staff Editor – Pathogenic bacteria have been enemies to human health for centuries. As recently as last month, the Centers for Disease Control published an 80-page document informing the public about America’s biggest microbial threats. Most of the pathogens on the list exhibit antibacterial resistance. One particular bacterial species, ranked at threat… |
![]() |
New Drug to Treat HIV-1 Hits the Market...
October 1, 2013 - Clinical , Featured By: Ada Seldin, Staff Editor – On August 12,2013, a new weapon against HIV-1 infection was added to the existing armada. Dolutegravir, the third integrase strand transfer inhibitor to attain FDA approval, targets a protein essential to HIV replication. HIV-1 is the predominant type of HIV virus, the other being HIV-2, which is endogenous to… |